SCHEMBL19975059

SCHEMBL19975059

COc1ccccc1N(C=O)C(C)C(=O)C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 1/20 0.43
APEX1 P27695 1/20 0.42
PLA2G1B P04054 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
PDE10A Q9Y233 1/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
CAPN1 P07384 1/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975540 1.00 CTSD (0.43) CTSDAPEX1PLA2G1BHTTL3MBTL1
SCHEMBL21183519 1.00 CTSD (0.43) CTSDAPEX1PLA2G1BHTTL3MBTL1
SCHEMBL19975394 0.92 TACR1 (0.39) ALDH1A1LMNAGAAMAPTCAPN1
SCHEMBL19974775 0.91 OPRM1 (0.42) CTSDAPEX1ALDH1A1LMNAPDE10A
SCHEMBL21176358 0.91 OPRM1 (0.42) CTSDAPEX1PLA2G1BHTTL3MBTL1
SCHEMBL19974810 0.90 POLB (0.48) ALDH1A1GAAMAPTSLC2A1
SCHEMBL19975196 0.90 CTSD (0.42) CTSDAPEX1PLA2G1BHTTL3MBTL1
SCHEMBL21183556 0.89 ADORA2A (0.43) HTTALDH1A1LMNAGAACAPN1
SCHEMBL19974858 0.89 ALDH1A1 (0.48) HTTL3MBTL1ALDH1A1LMNAGABRP
SCHEMBL19975281 0.89 ALDH1A1 (0.45) ALDH1A1LMNAGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C CTSD 922/4885APEX1 3061/4885PLA2G1B 1/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C CTSD 1046/4885APEX1 2716/4885PLA2G1B 2/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C CTSD 922/4885APEX1 3061/4885PLA2G1B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.